Galapagos' Strategic Shift: Betting On CAR-T And A Fresh Start (Rating Upgrade)
Galapagos shifts to CAR-T therapy with GLPG5101, targeting pivotal trials by 2026. Click here to find out why I rate GLPG ...
Galapagos price target lowered to EUR 22 from EUR 28 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Galapagos (GLPG) to EUR 22 from EUR 28 and keeps a Hold rating on the shares.Discover the Best ...
Galapagos NV (GLPG) (FY 2024) Earnings Call Highlights: Strategic Shifts and Financial Resilience
Galapagos NV (GLPG) reports strong financials and strategic advancements amid increased R&D expenses and operational ...
Galapagos projects 2026 pivotal trials for GLPG5101 following FDA clearance
CEO Paul Stoffels highlighted 2024 as a pivotal year for Galapagos, emphasizing the FDA IND clearance for GLPG5101 and strong results from the ATALANTA study in non-Hodgkin lymphoma. He outlined the ...
FierceBiotech7d
Galapagos drops one CD19 CAR-T to focus on 'flagship' program
Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate ...
Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update
Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to ...
precisionmedicineonline10d
Galapagos Partners With NecstGen to Support Decentralized Cell Therapy Manufacturing
NEW YORK – Galapagos said on Monday that it has partnered with NecstGen, a contract development and manufacturing organization (CDMO), to support decentralized manufacturing of Galapagos' cell therapy ...